Yes. We described it as post-market surveillance in the submission. We talked about it in supporting the progressive drug licensing framework.
On September 20th, 2006. See this statement in context.
On September 20th, 2006. See this statement in context.
Executive Director, Canadian Pharmacists Association
Yes. We described it as post-market surveillance in the submission. We talked about it in supporting the progressive drug licensing framework.
See context to find out what was said next.